STAT+: A Sellas immunotherapy study, long delayed, will end in failure

The prediction is based on delays that have raised significant doubts about the drug’s efficacy Molly Ferguson/STAT Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Sellas Life Sciences Group is a blowup waiting to happen. My prediction: Sellas’ experimental immunotherapy will fail to prolong survival compared to standard treatment for patients with acute myeloid leukemia in a second remission. I’m confident in my prediction the company’s Phase 3 REGAL study will have a negative outcome; I just don’t know when it will happen. The conclusion of the event-driven study has already been delayed by nearly a year — raising significant doubts about the efficacy of the Sellas treatment, called galinpepimut-S, or GPS. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.